BIODELIVERY SCIENCES INTL (BDSI)
Common Stock
BDSI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. BDSI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BDSI is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year BDSI was profitable.
In multiple years BDSI reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: BDSI reported negative operating cash flow in multiple years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.14% | ||
| ROE | 45.18% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.27% | ||
| PM (TTM) | 50.91% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for BDSI has been reduced compared to 1 year ago.
The debt/assets ratio for BDSI has been reduced compared to a year ago.
2.2 Solvency
BDSI has an Altman-Z score of 2.65. This is not the best score and indicates that BDSI is in the grey zone with still only limited risk for bankruptcy at the moment.
A Debt/Equity ratio of 0.29 indicates that BDSI is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.65 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BDSI has a Current Ratio of 2.45. This indicates that BDSI is financially healthy and has no problem in meeting its short term obligations.
BDSI has a Quick Ratio of 2.17. This indicates that BDSI is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 232.00% over the past year.
The Earnings Per Share has been growing by 71.95% on average over the past years. This is a very strong growth
The Revenue has been growing slightly by 6.54% in the past year.
The Revenue has been growing by 60.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y71.95%
EPS growth Q2Q520%
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y60.81%
Revenue growth Q2Q2.33%
3.2 Future
The Earnings Per Share is expected to grow by 21.10% on average over the next years. This is a very strong growth
BDSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.45% yearly.
EPS Next Y-57.48%
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
EPS Next 5Y21.1%
Revenue Next Year22.27%
Revenue Next 2Y24.06%
Revenue Next 3Y23.25%
Revenue Next 5Y23.45%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
BDSI is valuated cheaply with a Price/Earnings ratio of 6.73.
BDSI's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.02.
The Price/Forward Earnings ratio is 15.84, which indicates a correct valuation of BDSI.
BDSI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.58.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.73 | ||
| Fwd PE | 15.84 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.15 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.09
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
5. Dividend
5.1 Amount
No dividends for BDSI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODELIVERY SCIENCES INTL
NASDAQ:BDSI (3/22/2022, 8:00:02 PM)
After market: 5.6 +0.01 (+0.18%)5.59
0 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap552.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.73 | ||
| Fwd PE | 15.84 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.14% | ||
| ROE | 45.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.27% | ||
| PM (TTM) | 50.91% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y
EPS growth Q2Q
EPS Next Y-57.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y